Merck Propecia patient retention challenge is similar to that faced by company with Proscar.
Executive Summary
MERCK PROPECIA PATIENT RETENTION CHALLENGE REPRISES PROSCAR DILEMMA: as with the original finasteride formulation for benign prostatic hyperplasia, patients will need to take the new baldness product for a relatively lengthy trial period before they can expect improvement of a benign symptomatic condition. Merck will encourage a six-month minimum trial period for Propecia. Proscar is similarly labeled for a six-month trial to determine response. Merck was expecting approval of Propecia by the user fee deadline of Dec. 20.